Mylan

Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance

Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance

MORGANTOWN, W.Va., Oct. 25, 2019 /PRNewswire/ -- Mylan Pharmaceuticals Inc. is conducting a voluntary nationwide recall of one lot (see table below) of Alprazolam Tablets, USP C-IV 0.5 mg, to the consumer/user level. This lot is being recalled due to the potential presence of foreign substance. Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk...

Read More »
Company News

Mylan and Pfizer Receive Clearance from The U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Pfizer Announces Record Date for the Proposed Transaction Hertfordshire, England and Pittsburgh and New York, Oct. 30, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the FTC ) accepted a proposed consent order, which concludes the FTC's review of the proposed combination of Mylan and Pfizer's Upjohn Business....

Read More »
Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance

Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance

MORGANTOWN, W.Va., Oct. 25, 2019 /PRNewswire/ -- Mylan Pharmaceuticals Inc. is conducting a voluntary nationwide recall of one lot (see table below) of Alprazolam Tablets, USP C-IV 0.5 mg, to the consumer/user level. This lot is being recalled due to the potential presence of foreign substance. Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk...

Read More »
Company News

Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio

PITTSBURGH, March 22, 2011 - Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary UDL Laboratories, part of the Mylan Institutional business, has entered a license agreement with Humeca, a leading plastic surgery and burn treatment products company, for the exclusive U.S. distribution rights of Humeca products. Humeca, which is based in the Netherlands, has a portfolio that includes...

Read More »
Mergers & Acquisitions

Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected

Company also launches new Mylan Institutional business PITTSBURGH, Sept. 7 - Mylan Inc. (NASDAQ:MYL) today announced it has completed the acquisition of Bioniche Pharma Holdings Limited sooner than anticipated. Bioniche Pharma, an injectable pharmaceutical company, is providing Mylan with immediate entry into the North American injectables market and a platform for the commercialization of future...

Read More »

All Topics